Clinical Sciences - Viral Hepatitis/Antiretroviral Resistance

217 - VALIDATION OF A SIMPLE MODEL FOR PREDICTING LIVER FIBROSIS IN HIV/HEPATITIS C (HCV) CO-INFECTED PATIENTS

218 - DIRECTLY OBSERVED THERAPY (DOT) FOR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION IN INJECTION DRUG USERS (IDUs) – AN INTERIM ANALYSIS

219 - CONTRIBUTION OF DRUG USE AND LIFESTYLE TO HEPATIC FIBROSIS IN HIV-HEPATITIS C (HCV) CO-INFECTION

220 - CPG IMMUNE STIMULANT PLUS HBV VACCINE ACHIEVES SUSTAINED SEROPROTECTION FOR UP TO 42 MONTHS IN HIV INFECTION

221 - PREVALENCE AND LONG-TERM IMPLICATIONS OF BASELINE HIV RESISTANCE-ASSOCIATED MUTATIONS IN A LARGE COHORT OF ANTIRETROVIRAL-NAIVE INDIVIDUALS INITIATING THEIR FIRST ANTIRETROVIRAL TREATMENT

222 - EFFECTS OF BASELINE RESISTANCE MUTATIONS IN TREATMENT-NAïVE PATIENTS STARTING AN NNRTI-BASED REGIMEN

223 - A META-ANALYSIS TO DETERMINE THE TRANSMISSION RATE OF VARIOUS HIV-1 DRUG-RESISTANT

224 - PREDICTORS OF SELECTION OF D30N OVER THE L90M MUTATION IN TREATMENT FAILING PATIENTS